UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

An off-the-shelf cancer vaccine is associated with durable responses and a reduced risk of relapse and death among patients with pancreatic or colorectal cancers.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing safety/activity with novel therapies.

Blocking serotonin transporters with antidepressants boosted CD8 T cell function and enhanced immunotherapy response in mouse and human tumor models.

A new endoscopic tunneling method, STER, allowed a patient to have a GIST removed without surgery, allowing quicker recovery and fewer complications.

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers.

Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cervical cancer who are experiencing side effects.

Dr. Ritu Salani discussed Cervical Cancer Awareness Month, highlighting what patients with this disease should be aware of as well as prevention tactics.

Dr. Aditya Bardia shared his insights on what he believes are the top side effects to be aware of when undergoing ADC treatment for breast cancer.